

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

31 May 2026

### Evaluation of the effect of oral proliveon liver function in patients with major and intermediate thalassemia

#### Protocol summary

##### Study aim

The effect of oral prolio on hepatic parameters, patients with thalassemia major, and intremedia is determined.

##### Design

Double blind randomized clinical trial in Amir Kabir hospital in Arak. 40 patients with thalassemia major and Intermedia will be divided into two equal groups using block randomization method.

##### Settings and conduct

This clinical trial study will be performed on all patients with major beta-thalassemia over 5 years referred to Amir Kabir hospital. At baseline, liver enzymes levels of ALT, AST, total cholesterol, total protein, ALKp, total bilirubin and GGT will be measured by ELISA method. patients will be randomly divided into two groups. In the experimental group, the patients with age under 12 will receive half tablet and patients over 12 years will receive one tablet (275 mg) of oral Prolio twice daily (every 12 hours) and the placebo group will receive two placebo tablet twice daily. Patients will be treated 6 months and each month liver function tests will be performed. Then the information will be recorded.

##### Participants/Inclusion and exclusion criteria

in :All patients with beta thalassemia major and intermedia over 5 years Exit: Unwilling to participate

##### Intervention groups

At baseline, liver enzymes levels of ALT, AST, total cholesterol, total protein, ALKp, total bilirubin and GGT will be measured by ELISA in the control group. In the experimental group, patients under the age of 12 years will receive half a tablet and over 12 years one oral tablet (275 mg) of Prolio every 12 hours and in the control group patients will receive placebo control twice daily.

##### Main outcome variables

Hepatic parameters

#### General information

##### Reason for update

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20191010045050N1**

Registration date: **2020-01-05, 1398/10/15**

Registration timing: **registered\_while\_recruiting**

Last update: **2020-01-05, 1398/10/15**

Update count: **0**

##### Registration date

2020-01-05, 1398/10/15

##### Registrant information

##### Name

Azam Ebrahimi

##### Name of organization / entity

##### Country

Iran (Islamic Republic of)

##### Phone

+98 86 3312 7359

##### Email address

azame7733@gmail.com

##### Recruitment status

**Recruitment complete**

##### Funding source

##### Expected recruitment start date

2019-12-01, 1398/09/10

##### Expected recruitment end date

2020-02-29, 1398/12/10

##### Actual recruitment start date

empty

##### Actual recruitment end date

empty

##### Trial completion date

empty

##### Scientific title

Evaluation of the effect of oral proliveon liver function in patients with major and intermediate thalassemia

#### Public title

Evaluation of the effect of oral prolive on liver function in patients with major and intermediate thalassemia

#### Purpose

Treatment

#### Inclusion/Exclusion criteria

##### Inclusion criteria:

All patients with beta thalassemia major and intermedia over 5 years

##### Exclusion criteria:

Patients not willing to participate in the study Malignancy Liver dysfunction

#### Age

From **5 years** old to **18 years** old

#### Gender

Both

#### Phase

3

#### Groups that have been masked

- Participant
- Care provider
- Outcome assessor
- Data analyser

#### Sample size

Target sample size: **40**

#### Randomization (investigator's opinion)

Randomized

#### Randomization description

Randomization method: Block Randomization Unit:  
Individual Randomization Tool: Envelope Method How to Build a Random Sequence: Using  
www.randomization.com Explanation of concealment:  
Using non-transparent sealed envelopes with a random sequence

#### Blinding (investigator's opinion)

Double blinded

#### Blinding description

Only the researcher in this study will be aware of the study groups while the patients will be not aware of the type of drug being used. Also, the intern responsible for filling the checklists will be not aware of the type of medication consumed, and only will know the groups based on A and B and will fill out the checklists accordingly.

#### Placebo

Used

#### Assignment

Parallel

#### Other design features

#### Secondary Ids

empty

#### Ethics committees

#### 1

##### Ethics committee

###### Name of ethics committee

Ethics Committee of Arak University of Medical sciences

###### Street address

Arak University of Medical sciences ,Basij square , Sardasht

###### City

Arak

###### Province

Markazi

###### Postal code

3848176941

##### Approval date

2019-08-04, 1398/05/13

##### Ethics committee reference number

IR.ARAKMU.REC.1398.087

#### Health conditions studied

#### 1

##### Description of health condition studied

Major and intermedia thalassemia

##### ICD-10 code

D77

##### ICD-10 code description

Other disorders of blood and blood-forming organs in diseases classified elsewhere

#### Primary outcomes

#### 1

##### Description

Liver enzyme

##### Timepoint

Before the intervention and after, every one month to six months

##### Method of measurement

Laboratory

#### 2

##### Description

Total Billirubin and Total protein

##### Timepoint

Before the intervention and after, every one month to six months

##### Method of measurement

Laboratory

#### Secondary outcomes

empty

#### Intervention groups

## 1

### Description

Intervention group: At baseline, liver enzymes levels of ALT, AST, total cholesterol, total protein, ALKp, total bilirubin and GGT will be measured by ELISA in the control group. patients with age under 12 will receive half tablet and patients over 12 years will receive one tablet (275 mg) of oral Prolio twice daily (every 12 hours) and repeat tests up to 6 months each months.

### Category

Treatment - Drugs

## 2

### Description

Control group: At baseline, liver enzymes levels of ALT, AST, total cholesterol, total protein, ALKp, total bilirubin and GGT will be measured by ELISA in the control group. patients will receive two placebo tablet twice daily (every 12 hours) and repeat tests up to 6 months each month.

### Category

Treatment - Drugs

## Recruitment centers

### 1

#### Recruitment center

**Name of recruitment center**

Amir Kabir Hospital in Arak

**Full name of responsible person**

Azam Ebrahimi

**Street address**

Nursing square , Shahid Shirodi street

**City**

Arak

**Province**

Markazi

**Postal code**

3848176941

**Phone**

+98 86 3313 4715

**Email**

Rsearch@arakmu.ac.ir

## Sponsors / Funding sources

### 1

#### Sponsor

**Name of organization / entity**

Arak University of Medical Sciences

**Full name of responsible person**

Alireza Kamali

**Street address**

Arak Medical Science

**City**

Arak

**Province**

Markazi

**Postal code**

3848176941

**Phone**

+98 86 3313 4715

**Email**

Rsearch@arakmu.ac.ir

**Grant name****Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

**Title of funding source**

Arak University of Medical Sciences

**Proportion provided by this source**

100

**Public or private sector**

Public

**Domestic or foreign origin**

Domestic

**Category of foreign source of funding**

*empty*

**Country of origin****Type of organization providing the funding**

Academic

## Person responsible for general inquiries

#### Contact

**Name of organization / entity**

Arak University of Medical Sciences

**Full name of responsible person**

Azam Ebrahimi

**Position**

Medical Student

**Latest degree**

A Level or less

**Other areas of specialty/work**

Pediatrics

**Street address**

91 Alley - Emam Khomeini Street

**City**

Esfahan

**Province**

Isfahan

**Postal code**

8139949551

**Phone**

+98 86 3312 7359

**Email**

azame7733@gmail.com

## Person responsible for scientific inquiries

#### Contact

**Name of organization / entity**

Arak University of Medical Sciences

**Full name of responsible person**

Azam Ebrahimi

**Position**

Intern

**Latest degree**

A Level or less  
**Other areas of specialty/work**  
Pediatrics  
**Street address**  
Alley 91 - Emam khomeini street  
**City**  
Esfahan  
**Province**  
Isfahan  
**Postal code**  
8139949551  
**Phone**  
+98 86 3312 7359  
**Fax**  
**Email**  
www.azame7733@gmail.com

## Person responsible for updating data

### Contact

**Name of organization / entity**  
Arak University of Medical Sciences  
**Full name of responsible person**  
Azam Ebrahimi  
**Position**  
Intern  
**Latest degree**  
A Level or less  
**Other areas of specialty/work**  
Pediatrics  
**Street address**  
Alley 91 - Emam khomeini street  
**City**

Esfahan  
**Province**  
Isfahan  
**Postal code**  
8139949551  
**Phone**  
+98 86 3312 7359  
**Fax**  
**Email**  
www.azame7733@gmail.com

## Sharing plan

### Deidentified Individual Participant Data Set (IPD)

Undecided - It is not yet known if there will be a plan to make this available

### Study Protocol

Undecided - It is not yet known if there will be a plan to make this available

### Statistical Analysis Plan

Undecided - It is not yet known if there will be a plan to make this available

### Informed Consent Form

Undecided - It is not yet known if there will be a plan to make this available

### Clinical Study Report

Undecided - It is not yet known if there will be a plan to make this available

### Analytic Code

Undecided - It is not yet known if there will be a plan to make this available

### Data Dictionary

Undecided - It is not yet known if there will be a plan to make this available